litlas
Log inCreate account

Josep Tabernero

Active 1995–2026

463
Papers
115,757
Citations
147
h-index
442
i10-index

Citations

Citations per year for Josep Tabernero1990: 3 citations1991: 3 citations1993: 2 citations1996: 2 citations1997: 1 citations1998: 1 citations1999: 5 citations2000: 3 citations2001: 8 citations2002: 8 citations2003: 4 citations2004: 30 citations2005: 90 citations2006: 107 citations2007: 122 citations2008: 151 citations2009: 184 citations2010: 315 citations2011: 427 citations2012: 497 citations2013: 649 citations2014: 893 citations2015: 1,004 citations2016: 1,143 citations2017: 1,410 citations2018: 1,296 citations2019: 4,519 citations2020: 5,249 citations2021: 5,192 citations2022: 4,015 citations2023: 3,441 citations2024: 5,550 citations2025: 2,890 citations2026: 123 citations1992: no citations, so this year is not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 10,258 citing papers, 22% of this breakdownChina: 6,273 citing papers, 13.5% of this breakdownItaly: 2,775 citing papers, 6% of this breakdownUnited Kingdom: 2,642 citing papers, 5.7% of this breakdownGermany: 2,402 citing papers, 5.1% of this breakdownFrance: 1,973 citing papers, 4.2% of this breakdownSpain: 1,904 citing papers, 4.1% of this breakdownJapan: 1,879 citing papers, 4% of this breakdownNetherlands: 1,319 citing papers, 2.8% of this breakdownCanada: 1,194 citing papers, 2.6% of this breakdownAustralia: 1,078 citing papers, 2.3% of this breakdownSouth Korea: 1,060 citing papers, 2.3% of this breakdown
0%22%Other 25.4%

Institutions

Fields

  • Medicine57.4%
  • Biochemistry, Genetics and Molecular Biology33.6%
  • Immunology and Microbiology3.2%
  • Engineering0.9%
  • Materials Science0.8%
  • Computer Science0.7%
  • Other3.4%

Topics

  • Colorectal Cancer Treatments and Studies5%
  • Cancer Genomics and Diagnostics4.5%
  • Cancer Immunotherapy and Biomarkers4%
  • Pancreatic and Hepatic Oncology Research3.4%
  • Genetic factors in colorectal cancer2.7%
  • Cancer Cells and Metastasis2.2%
  • Other78.2%

Coauthors

All papers

Open in search
  1. The consensus molecular subtypes of colorectal cancer

    Authors: Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laëtitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino, Brian M. Bot, Jeffrey S. Morris, Iris Simón, Sarah Gerster, Evelyn Fessler, Felipe de Sousa e Melo, Edoardo Missiaglia, Hena R. Ramay, David Barras, Krisztián Homicskó, Dipen Maru, Ganiraju C. Manyam, Bradley M. Broom, Valérie Boige, Beatriz Pérez‐Villamil, Ted Laderas, Ramón Salazar, Joe W. Gray, Douglas Hanahan, Josep Tabernero, René Bernards, Stephen Friend, Pierre Laurent‐Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk F.A. Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar - Nature Medicine 2015 cited by 5,259

  2. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Authors: Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel A. Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, José Iglesias, Markus F. Renschler - New England Journal of Medicine 2013 cited by 6,661

  3. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

    Authors: Susan Bullman, Chandra Sekhar Pedamallu, Ewa Sicińska, Thomas E. Clancy, Xiaoyang Zhang, Diana Cai, Donna Neuberg, Katherine Huang, Fatima Guevara, Timothy Nelson, Otari Chipashvili, Timothy Hagan, Mark Walker, Aruna Ramachandran, Begoña Diosdado, Garazi Serna, Nuria Mulet, Stefania Landolfi, Santiago Ramón y Cajal, Roberta Fasani, Andrew J. Aguirre, Kimmie Ng, Elena Élez, Shuji Ogino, Josep Tabernero, Charles S. Fuchs, William C. Hahn, Paolo Nucíforo, Matthew Meyerson - Science 2017 cited by 1,563

  4. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Guillem Argilés, Josep Tabernero, Roberto Labianca, Daniel Hochhauser, Ramón Salazar, Timothy Iveson, Pierre Laurent‐Puig, Philip Quirke, Takayuki Yoshino, Julien Taı̈eb, Erika Martinelli, Dirk Arnold - Annals of Oncology 2020 cited by 1,327

  5. The landscape of somatic copy-number alteration across human cancers

    Authors: Rameen Beroukhim, Craig H. Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S. Boehm, Jennifer Dobson, Mitsuyoshi Urashima, Kevin T. Mc Henry, Reid M. Pinchback, Azra H. Ligon, Yoon‐Jae Cho, Leila Haery, Heidi Greulich, Michael Reich, Wendy Winckler, Michael S. Lawrence, Barbara A. Weir, Kumiko Tanaka, Derek Y. Chiang, Adam J. Bass, Alice Loo, Carter Hoffman, John R. Prensner, Ted Liefeld, Qing Gao, Derek Yecies, Sabina Signoretti, Elizabeth A. Maher, Frederic J. Kaye, Hidefumi Sasaki, Joel E. Tepper, Jonathan A. Fletcher, Josep Tabernero, José Baselga, Ming‐Sound Tsao, Francesca Demichelis, Mark A. Rubin, Pasi A. Jänne, Mark J. Daly, Carmelo Nucera, Ross L. Levine, Benjamin L. Ebert, Stacey Gabriel, Anil K. Rustgi, Cristina R. Antonescu, Marc Ladanyi, Anthony Letai, Levi A. Garraway, Massimo Loda, David G. Beer, Lawrence D. True, Aikou Okamoto, Scott L. Pomeroy, Samuel Singer, Todd R. Golub, Eric S. Lander, Gad Getz, William R. Sellers, Matthew Meyerson - Nature 2010 cited by 4,185

  6. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

    Authors: Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang, Charles S. Fuchs, Lucjan Wyrwicz, Keun‐Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Christian Caglevic, Luis J. Villanueva-Rivera, Eray Goekkurt, Hironaga Satake, Peter C. Enzinger, María Alsina, Al B. Benson, Joseph Chao, Andrew H. Ko, Zev A. Wainberg, Uma Kher, Sukrut Shah, Soonmo Peter Kang, Josep Tabernero - JAMA Oncology 2020 cited by 1,125

  7. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

    Authors: Aleksandar D. Kostic, Dirk Gevers, Chandra Sekhar Pedamallu, Monia Michaud, Fujiko Duke, Ashlee M. Earl, Akinyemi I. Ojesina, Joonil Jung, Adam J. Bass, Josep Tabernero, José Baselga, Chen Liu, Ramesh A. Shivdasani, Shuji Ogino, Bruce W. Birren, Curtis Huttenhower, Wendy S. Garrett, Matthew Meyerson - Genome Research 2011 cited by 1,969

  8. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Authors: Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero - New England Journal of Medicine 2019 cited by 1,465

  9. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Authors: Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz‐Josef Lenz, Richard M. Goldberg, Daniel J. Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent - The Lancet 2012 cited by 2,897

  10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: Eric Van Cutsem, Andrés Cervantes, René Adam, Alberto Sobrero, J. Han van Krieken, Dan Aderka, E. Aranda Aguilar, Alberto Bardelli, Al B. Benson, G. Bodoky, Fortunato Ciardiello, André D’Hoore, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Michel Ducreux, Alfredo Falcone, Axel Grothey, Thomas Gruenberger, Karin Haustermans, Volker Heinemann, Paulo M. Hoff, C.-H. Köhne, Roberto Labianca, Pierre Laurent‐Puig, Brigette Ma, Tim Maughan, Kei Muro, Nicola Normanno, Pia Österlund, Wim J.G. Oyen, Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  11. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

    Authors: Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, Ning Li, Sara Lonardi, О. P. Коlesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung - Nature 2021 cited by 709

  12. Clinical management of metastatic colorectal cancer in the era of precision medicine

    Authors: Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andrés Cervantes - CA A Cancer Journal for Clinicians 2022 cited by 539

  13. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

    Authors: Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin Kate Kelley, Philippe A. Cassier, Heinz‐Josef Klümpen, Heung-Moon Chang, Li‐Tzong Chen, Josep Tabernero, Do‐Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel H. Ahn, Robert S. Epstein, Abdel‐Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John Bridgewater - New England Journal of Medicine 2023 cited by 541

  14. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

    Authors: Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Kan Li, Chie‐Schin Shih, Pooja Bhagia, Sun Young Rha - The Lancet 2023 cited by 467

  15. Current developments in gastric cancer: from molecular profiling to treatment strategy

    Authors: María Alsina, Virginia Arrazubi, Marc Díez, Josep Tabernero - Nature Reviews Gastroenterology & Hepatology 2022 cited by 362

  16. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Authors: Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero - New England Journal of Medicine 2023 cited by 428

  17. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Authors: Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio García‐Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Éveline Boucher, Marc Peeters, Ben Tran, Heinz‐Josef Lenz, Alberto Zaniboni, Howard S. Höchster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu - New England Journal of Medicine 2015 cited by 1,431

  18. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    Authors: Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar García‐Alfonso, Elena Élez, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Scott Kopetz - Journal of Clinical Oncology 2021 cited by 544

  19. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean‐Yves Blay, Jürgen Wolf, Noopur Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoîne Italiano, Ralf‐Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schüler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzén, Maria Luisa Veronese, Josep Tabernero, José Baselga - New England Journal of Medicine 2015 cited by 1,734

  20. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

    Authors: Leticia De Mattos‐Arruda, Regina Mayor, Charlotte K.Y. Ng, Britta Weigelt, Francisco Martínez‐Ricarte, Davis Y. Torrejon, Mafalda Oliveira, Alexandra Arias, C. Raventós, Jiabin Tang, Elena Guerini‐Rocco, Elena Martínez‐Sáez, Sergio Lois, Óscar Marín, Xavier de la Cruz, Salvatore Piscuoglio, Russel Towers, Ana Vivancos, Vicente Peg, Santiago Ramón y Cajal, Joan Carles, Jordi Rodón, María González‐Cao, Josep Tabernero, Enriqueta Felip, Juan Sahuquillo, Michael F. Berger, Javier Cortés, Jorge S. Reis‐Filho, Joan Seoane - Nature Communications 2015 cited by 858

  21. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    Authors: Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng - The Lancet 2023 cited by 323

  22. Enhancing anti-tumour efficacy with immunotherapy combinations

    Authors: Funda Meric‐Bernstam, James Larkin, Josep Tabernero, Chiara Bonini - The Lancet 2020 cited by 435

  23. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    Authors: Joseph Chao, Charles S. Fuchs, Kohei Shitara, Josep Tabernero, Kei Muro, Eric Van Cutsem, Yung‐Jue Bang, Ferdinando De Vita, Gregory Landers, Chia‐Jui Yen, Ian Chau, Anneli Elme, Jeeyun Lee, Mustafa Özgüroğlu, Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David E. Adelberg, Chie‐Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg - JAMA Oncology 2021 cited by 443

  24. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    Authors: Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar, Josep Tabernero - Nature reviews. Cancer 2017 cited by 1,030